|
NOTICE:
UTILITY OF AN ORAL PRESENTATION OF hCG (human Choriogonadotropin) FOR THE MANAGEMENT OF OBESITY. |
CONTENTS
|
Abstract
Female
obese volunteers participating in a double blind study, and
submitted to the administration of an oral presentation of hCG
(Human Choriogonadotropin) plus a VLCD (Very Low Calorie Diet),
decreased specific body circumferences and skinfold thickness from
conspicuous body areas more efficiently than Placebo+VLCD -treated
subjects.
Since a significant fat proportion from
total body fat is subcutaneously located (50 to 65 percent,
depending on sex and fat distribution), this hCG metabolic
activity would result in a reduction of the total body fat mass,
the main cause for obesity. We suggested that the combination of a
VLCD and oral hCG could not only trigger clinically significant
changes in subcutaneous fat stores but simultaneously decrease
body weight and modelate body contour.
hCG oral
administration proved to be a safe and effective procedure on
obese treated volunteers. No side effects were observed in the
course of the study. There are no reports in the literature
regarding this administration route to compare our findings.
Compared
to placebo treated subjects, volunteers managed with an oral
administration of hCG coped more efficiently with daily irritating
situations, were in a better mood, and handled home conflicts
without stepping up family discussions.
KEYWORDS:
Gonadotrophin), Chorionic; Obesity; Adipose tissue metabolism;
fat ; overweight; beta-endorphin; lypolisis; lypogenesis.
Introduction
Quite few substances have been so neglected and misunderstood regarding its potential therapeutic effects as hCG, the acronym for Human Chorionic
Gonadotrophin.
First discovered by Ascheim and Zondek as back as 1927 in the urine from pregnant women (2,67), thousands of articles were published regarding its action on gonads, but comparatively quite a few investigated its vast therapeutics potentialities, encompassing Kaposi sarcoma (33,42,49,77), asthma (63,66), mood and psychiatric disorders
(22,23,28,60), artheriopaties
(14), thalassemia (7,19,56), osteopenia (56), glaucoma (53).
hCG is the glycoproteic hormone normally secreted by trophoblastic cells of the placenta during pregnancy (67). It consists of two dissimilar, separately, but most presumably coordinately translated chains, called the alpha and beta subunits. (12,18,25,26,30,46)
The three pituitary hormones LH (Luteinising Hormone), FSH (Follicle Stimulating Hormone) and TSH (Thyroid Stimulating Hormone) are closely related to hCG in that all four are glycosilated and have a dimeric structure comprising the alpha and beta chains as well. (29,30,34,78,79)
The aminoacid sequence of alpha chain of all four human glycoproteic hormones is nearly identical (58). The aminoacid sequence of the Beta subunits differs and account for by the unique immunological and biological activities of each glycoproteic hormone (62). Beta hCG contains a carboxylic residue of 30 aminoacids characteristic to hCG (11,51)
Its denomination (Human Chorionic Gonadotropin) dates back from the early days, when it was found hCG rendered mature the infantile sex glands in experimentation animals (Gonadotropin) and it was secreted by the placentary chorion (Chorionic) (2,90).
However, recent data suggests both terms can be quite misleading: normal human tissues from non-pregnant subjects (47,74,86,87,89), trophoblastic and non-trophoblastic tumors (6,32,89), bacteria (48), and plants (45,69) express hCG or an hCG-like substance.
The first report on hCG and obesity was published back as 1954 in The Lancet, by a British physician, Dr. A.T.W. Simeons (70,71). After its publication, hCG was advocated for several years as a useful approach to obesity. The pendulum of its popularity swinged back and forth until a serial of studies (1,3,8,17,35,50) but
five (3,20,24,80,80b) concluded hCG was of no use to manage the disease
According to basic pharmacological postulates, the administration route may influence the biological activity of a drug. All previous studies were performed with an hCG preparation administered by injections. One of the authors of this study (DB) theorized that an increase in dose and a shifting in hCG administration to a sublingual-enteral route may modify the pharmacological activity of hCG.
The purpose of this study was to assess the utility of an oral presentation hCG for the management of
obesity.
(Materials and methods, Clinicometric controls) |
|
NOTICE:
The oral hCG protocol for weight loss is© Dr. Daniel Belluscio.
All rights reserved (please browse clicking here )
